TDC
SAGE

Thompson Davis & Co’s Sage Therapeutics SAGE Stock Holding History

Thompson Davis & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-290
Closed -$18K – 1010
2017
Q3 		$18K Buy
290
+92
+46% +$7.23K 0.03% 514
2017
Q2 		$16K Hold
198
– – 0.03% 541
2017
Q1 		$14K Hold
198
– – 0.02% 606
2016
Q4 		$10K Buy
+198
New +$9.33K 0.02% 705

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Thompson Davis & Co's SAGE Position: Q4 2017 in Review

Thompson Davis & Co sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 290 shares — an estimated $18K sold.

Thompson Davis & Co first reported a position in SAGE in Q4 2016 and held it in 4 quarters. The position peaked at $18K in Q3 2017. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

  • Thompson Davis & Co reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 290 Sage Therapeutics shares in Q4 2017, an estimated $18K.
  • Thompson Davis & Co first reported a position in Sage Therapeutics in Q4 2016 and held it in 4 quarters.
  • Thompson Davis & Co's Sage Therapeutics position peaked at $18K in Q3 2017.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.